Author

Meredith Todd

Observed name: M Todd

Observed institutions: Columbia University Irving Medical Center, Cardiovascular Research Foundation, Scripps Clinic, Medicines Company (United States)

OpenAlex ID: A5059307070

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

2013 · Deepak L. Bhatt, Gregg W. Stone, et al. · New England Journal of Medicine · 848

Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.

2001 · D J Kereiakes, C Grines, et al. · PubMed · 143

Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention

2013 · Philippe Généreux, Gregg W. Stone, et al. · Journal of the American College of Cardiology · 108

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial

2012 · Sergio Leonardi, Kenneth W. Mahaffey, et al. · American Heart Journal · 79

Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience

2016 · Sergio Leonardi, Renato D Lopes, et al. · European Heart Journal Acute Cardiovascular Care · 9

Safety and Efficacy of Cangrelor, an Intravenous, Short-Acting Platelet Inhibitor in Patients Requiring Coronary Artery Bypass Surgery

2013 · Michael S. Firstenberg, Cornelius M. Dyke, et al. · The Heart Surgery Forum · 7

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel From the Champion Phoenix Trial

2014 · Philippe Genereux, Robert Harrington, et al. · Journal of the American College of Cardiology · 4

Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes

2013 · Sergio Leonardi, Amanda Stebbins, et al. · Coronary Artery Disease · 3

OC.55 Reconnoiter-1: a phase 2, prospective, blinded, randomized, parallel-group and crossover clinical trial evaluating AISA-021, a novel ccb, in subjects with Raynaud’s phenomenon (SSc-RP

2026 · Francesco DelGaldo, Michael Shanahan, et al.

Works count: 9

Citation count: 1,201

H-index: 6

I10-index: 4